Navigation Links
Patent for Making Combination Chemotherapy Work Better
Date:3/24/2009

SAN JOSE, Calif., March 24 /PRNewswire/ -- Patent 7,507,704 issued on 03/24/09 to NexGen Biomedical, Inc. founder Mark Zamoyski of San Jose, California discloses an improved method of treating lung, brain, pancreatic, breast and colon cancers that are driven by a mutation known as HER1 overexpression (also called EGFR or c-ErbB-1). The patent presents a case for why today's concurrent HER1 blocker / S-Phase cytotoxic protocols achieve only a fraction of the potential inherent in the combination of the underlying drugs. Novel synergistic protocols are provided.

All proliferating cells progress through 4 distinct phases, in sequence, G1, S, G2, and M. "S-Phase cytotoxics, such as Pfizer's irinotecan or Eli Lilly's gemcitabine, are capable of killing virtually all cells that are in the S-Phase, however, less than one third of cancer cells are typically in the S-Phase during chemotherapy," explains Mark Zamoyski, the inventor. "Mechanistically, HER1 blockers, such as Genentech's erlotinib, AstraZeneca's gefitinib, ImClone's cetuximab and Amgen's panitumumab arrest and aggregate HER1 overexpressing cancer cells in the G1-Phase. This results in S-Phase depletion, greatly reducing the number of cancer cells killed by the S-Phase cytotoxic." The patent provides a crucial modification to the protocols by adding existing drugs to provide S-Phase enrichment at the appropriate time, while using the HER1 blocker to inhibit tumor regrowth between administrations of S-Phase cytotoxic.

Patent 7,507,704 is the third in a series of patents awarded to Mr. Zamoyski for cancer specific S-Phase enrichment relative to administrations of S-Phase cytotoxic chemotherapy. "With less than one third of cancer cells in the S-Phase, today's cytotoxic protocols only extend life expectancy by a few months. Doubling the number of cancer cells in the S-Phase would provide a way of indefinitely keeping most cancers in check. Tripling the number, while simultaneously preventing tumor regrowth between administrations of S-Phase cytotoxic, is required under established principles of chemotherapy for curative outcome. Drugs capable of doing both already exist for many cancers, providing the potential for an immediate advance in cancer treatment under our protocols," according to Mr. Zamoyski. Richard Lepidi, NexGen's business advisor, concludes "The IP has now reached a critical mass that allows us to pursue business collaborations for clinical development of the technology."

More information is available at www.nexgen.biz under Cell Cycle Synchronous Chemotherapy.


'/>"/>
SOURCE NexGen Biomedical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Confirmation of Bogoch Replikins Influenza Patents by Harvard-CDC and Scripps-Crucell Data
2. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
3. Intradigm Receives Notice of Allowance for Key RNA Interference (RNAi) Patent Covering Potent siRNA Sequence
4. Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents
5. VIASPACE Granted US Patent
6. InNexus Biotechnology Announces New Patents Protecting Novel Cell Penetrating DXL(TM) Antibodies
7. VIA Pharmaceuticals Announces Grant of New Patent on Lead Compound VIA-2291
8. Mindset BioPharmaceuticals (USA) Inc Obtains Notice of Allowance for European Patent Related to Use of Insulin Sensitizers in Senile Dementia, Dementia and Memory Loss
9. InterMune Announces Issuance of U.S. Patent for ITMN-191
10. Odyssey Thera Granted U.S. Patent for Novel GPCR Assay Strategy
11. Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , ... June 24, 2016 , ... Researchers at the ... commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject ... it now. , Diagnostic biomarkers are signposts in the blood, lung fluid or ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software ... State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , ... Tremblay, President and COO of STACS DNA. “In further expanding our capacity as a ...
Breaking Biology Technology:
(Date:6/27/2016)... 2016 Research and Markets has announced the ... report to their offering. The ... to grow at a CAGR of 12.28% during the period ... an in-depth market analysis with inputs from industry experts. The report ... years. The report also includes a discussion of the key vendors ...
(Date:6/22/2016)... Md. , June 22, 2016  The American College ... Trade Show Executive Magazine as one of the ... on May 25-27 at the Bellagio in Las ... on the highest percentage of growth in each of the ... of exhibiting companies and number of attendees. The 2015 ACMG ...
(Date:6/22/2016)... June 22, 2016   Acuant , ... verification solutions, has partnered with RightCrowd ® ... for Visitor Management, Self-Service Kiosks and Continuous ... that add functional enhancements to existing physical ... and venues with an automated ID verification ...
Breaking Biology News(10 mins):